title: Aspirin for acute coronary syndromes: have we learned the correct dose yet?
abstract: Despite its universal use, the optimal dose of aspirin from an efficacy and safety perspective remains unclear. There are wide variations in international practice and a lack of consensus as to the most appropriate dose of aspirin in patients with acute coronary syndromes (ACS), mainly because of the wide range of doses evaluated in early randomized trials of aspirin versus placebo. Comparisons of aspirin dose have been based on observational studies or indirect comparisons from meta-analysis of antiplatelet trials. These studies have suggested that aspirin, in doses>or=300 mg, is similar to aspirin doses 75-100 mg/d for prevention of major vascular events, but that higher doses increase the risk of major bleeding complications. Recently, the CURRENT-OASIS study, a randomized head-to-head comparison of higher-dose (>or=300 mg/d) versus low-dose aspirin (75-81 mg/d) for 1 month in over 25,000 patients with ACS referred for an early invasive strategy demonstrated similar outcomes between higher- and low-dose aspirin for efficacy, with no difference in the risk of major bleeding complications. Results from this mega-trial suggest that low-dose or higher-dose aspirin is a reasonable option in ACS patients undergoing an early invasive strategy.
authors.affiliation: Hamilton Health Sciences, David Braley Cardiac Vascular and Stroke Institute, C3-11A, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada. kbainey@ualberta.ca
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Bainey
authors.forename: Shamir R
authors.initials: SR
authors.lastname: Mehta
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D012307:Risk Factors; D040242:Risk Reduction Behavior; D055502:Secondary Prevention
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
references.citation: N Engl J Med. 2001 Aug 16;345(7):494-502
references.pmid: 11519503
references.citation: N Engl J Med. 2006 Apr 20;354(16):1706-17
references.pmid: 16531616
references.citation: Lancet. 1988 Aug 13;2(8607):349-60
references.pmid: 2899772
references.citation: Circulation. 2007 Aug 14;116(7):e148-304
references.pmid: 17679616
references.citation: BMJ. 2002 Jan 12;324(7329):71-86
references.pmid: 11786451
references.citation: Eur Heart J. 2009 Apr;30(8):900-7
references.pmid: 18819961
references.citation: N Engl J Med. 1985 Nov 28;313(22):1369-75
references.pmid: 3903504
references.citation: Lancet. 1990 Oct 6;336(8719):827-30
references.pmid: 1976875
references.citation: Ann Intern Med. 2009 Mar 17;150(6):379-86
references.pmid: 19293071
references.citation: Eur Heart J. 2007 Jul;28(13):1598-660
references.pmid: 17569677
references.citation: Circulation. 2003 Oct 7;108(14):1682-7
references.pmid: 14504182
references.citation: Circulation. 2003 Jul 29;108(4):399-406
references.pmid: 12874182
references.citation: N Engl J Med. 1983 Aug 18;309(7):396-403
references.pmid: 6135989
references.citation: Circulation. 2006 Feb 14;113(6):e85-151
references.pmid: 16407573
references.citation: Lancet. 2001 Aug 18;358(9281):527-33
references.pmid: 11520521
references.citation: N Engl J Med. 1988 Oct 27;319(17):1105-11
references.pmid: 3050522